MPLT insider ownership: who sold, why, and what they still hold

What stands out

Three directors bought shares: George Pavlov (25K shares, $441K), Timothy Garnett (14K shares, $253K) and Troy Cox (16K shares, $149K). These are the first purchases by current officers or directors in the filings on record.George Pavlov: purchase, Feb 18, 2026 · Timothy Garnett: purchase, Feb 10, 2026 · Troy Cox: purchase, Jul 28, 2026

A share of stake is shown for 0 of the 8 officers and directors who sold. 14 are left out

Left out: Erin Foff, Vishwas Setia, Kristopher Hanson, Christopher Kroeger, Robert Malenka, Maria Walker, Timothy Garnett, James Lillie, Jonathan Gillis, Anatol Kreitzer, Nanna Luneborg, George Pavlov, Martin Babler and Troy Cox (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Christopher Kroeger

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$12.5M52% planned, 48% to cover taxes

Jonathan Gillis

CAO and Interim CFO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.6M97% planned, 3% to cover taxes

Erin Foff

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.4M97% planned, 3% to cover taxes

Anatol Kreitzer

Chief Discovery Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.8M97% planned, 3% to cover taxes

James Lillie

Chief Scientific Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.6M69% planned, 31% to cover taxes

All 8 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 16, 2026Kristopher Hanson sold 17K shares ($193K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Kristopher Hanson General Counsel	16,509	$11.67	n/a	n/a	Sep 16, 2026	Sep 18, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Outside holders, reported separately

Novo Holdings A/S and Catalyst4, Inc. reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the MapLight Therapeutics, Inc. CEO selling stock?

Yes. Christopher Kroeger sold 403K shares ($12.5M) in the past 12 months, 52% of it under a trading plan disclosed in the filings.

Why are MapLight Therapeutics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 69% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 31% were to cover taxes. A trading plan schedules sales in advance.

Are any MapLight Therapeutics, Inc. insiders buying?

Yes. 3 officers or directors reported 5 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold8 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Christopher Kroeger Chief Executive Officer, Director	$12.5M 403K shares	Not confirmed share of stake is being verified. Why	52% under a disclosed plan, 48% to cover taxes
Jonathan Gillis CAO and Interim CFO	$3.6M 110K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
Erin Foff Chief Medical Officer	$3.4M 105K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
Anatol Kreitzer Chief Discovery Officer	$2.8M 85K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
James Lillie Chief Scientific Officer	$2.6M 97K shares	Not confirmed share of stake is being verified. Why	69% under a disclosed plan, 31% to cover taxes
Kristopher Hanson General Counsel	$1.7M 63K shares	Not confirmed share of stake is being verified. Why	60% under a disclosed plan, 40% to cover taxes
Robert Malenka Director	$1.6M 83K shares	Not confirmed share of stake is being verified. Why	14% under a disclosed plan, 86% to cover taxes
Vishwas Setia Chief Financial Officer	$1.1M 39K shares	Not confirmed share of stake is being verified. Why	93% under a disclosed plan, 7% to cover taxes

Outside holder, reported separately: Novo Holdings A/S (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Catalyst4, Inc. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Erin Foff

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Erin Foff are complete.

Chief Medical Officer

n/a

−105K

n/a

Vesting, gifts, unvested awards and holding lines for Erin Foff

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Erin Foff are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−45Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
82,619	$5.55	Feb 16, 2032	$506K
15,476	$5.55	Mar 10, 2032	$95K
196,035	$17.00	Oct 26, 2035	$0
54,240	$15.70	Feb 4, 2036	$0
54,240	$11.24	Aug 16, 2036	$23K

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Vishwas Setia

Chief Financial Officer

n/a

−39K

n/a

Vesting, gifts, unvested awards and holding lines for Vishwas Setia

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Vishwas Setia are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−33Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
176,031	$17.00	Oct 26, 2035	$0
31,395	$15.70	Feb 4, 2036	$0

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Kristopher Hanson

General Counsel

n/a

−63K

n/a

Vesting, gifts, unvested awards and holding lines for Kristopher Hanson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kristopher Hanson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−26Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
43,333	$9.92	Jun 27, 2033	$76K
110,046	$17.00	Oct 26, 2035	$0
31,395	$15.70	Feb 4, 2036	$0
31,395	$11.24	Aug 16, 2036	$13K

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Christopher Kroeger

Chief Executive Officer, Director

n/a

−403K

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Kroeger

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Kroeger are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−204Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
98,448	$2.86	Oct 7, 2029	$867K
77,380	$5.55	Feb 16, 2032	$474K
49,107	$5.55	Mar 10, 2032	$301K
916,164	$17.00	Oct 26, 2035	$0
93,955	$15.70	Feb 4, 2036	$0
93,955	$11.24	Aug 16, 2036	$40K

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Robert Malenka

Director

n/a

−83K

n/a

Vesting, gifts, unvested awards and holding lines for Robert Malenka

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Malenka are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,892	$5.55	Feb 16, 2032	$158K
22,321	$5.55	Mar 10, 2032	$137K
139,610	$17.00	Oct 26, 2035	$0

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Maria Walker

Director

n/a

Vesting, gifts, unvested awards and holding lines for Maria Walker

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Maria Walker are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,604	$17.00	Oct 26, 2035	$0
14,902	$28.64	Jun 22, 2036	$0

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Timothy Garnett

Director

n/a

Vesting, gifts, unvested awards and holding lines for Timothy Garnett

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Timothy Garnett are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,047	$9.92	Jul 25, 2033	$18K
25,604	$17.00	Oct 26, 2035	$0
14,902	$28.64	Jun 22, 2036	$0

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

James Lillie

Chief Scientific Officer

n/a

−97K

n/a

Vesting, gifts, unvested awards and holding lines for James Lillie

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Lillie are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−45Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
22,082	$2.86	Oct 7, 2029	$195K
17,857	$5.55	Feb 16, 2032	$109K
13,988	$5.55	Mar 10, 2032	$86K
132,023	$17.00	Oct 26, 2035	$0
31,395	$15.70	Feb 4, 2036	$0
31,395	$11.24	Aug 16, 2036	$13K

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Jonathan Gillis

CAO and Interim CFO

n/a

−110K

n/a

Vesting, gifts, unvested awards and holding lines for Jonathan Gillis

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jonathan Gillis are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−22Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
16,440	$2.86	Oct 7, 2029	$145K
10,960	$5.55	Feb 16, 2032	$67K
7,440	$5.55	Mar 10, 2032	$46K
124,022	$17.00	Oct 26, 2035	$0
24,455	$15.70	Feb 4, 2036	$0
24,455	$11.24	Aug 16, 2036	$10K
2,813	$11.24	Aug 16, 2036	$1K

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Anatol Kreitzer

Chief Discovery Officer

n/a

−85K

n/a

Vesting, gifts, unvested awards and holding lines for Anatol Kreitzer

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Anatol Kreitzer are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−42Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
16,440	$2.86	Oct 7, 2029	$145K
16,600	$2.86	Jan 27, 2030	$146K
8,928	$5.55	Feb 16, 2032	$55K
22,916	$5.55	Mar 10, 2032	$140K
146,052	$17.00	Oct 26, 2035	$0
24,455	$15.70	Feb 4, 2036	$0
24,455	$11.24	Aug 16, 2036	$10K

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Nanna Luneborg

Director

n/a

Vesting, gifts, unvested awards and holding lines for Nanna Luneborg

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Nanna Luneborg are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,902	$28.64	Jun 22, 2036	$0

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

George Pavlov

Director

n/a

Vesting, gifts, unvested awards and holding lines for George Pavlov

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for George Pavlov are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,902	$28.64	Jun 22, 2036	$0

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Martin Babler

Director

n/a

Vesting, gifts, unvested awards and holding lines for Martin Babler

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Martin Babler are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
29,804	$28.64	Jun 22, 2036	$0

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Troy Cox

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Troy Cox are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Troy Cox

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Troy Cox are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
29,804	$28.64	Jun 22, 2036	$0

Estimate: options held × ($11.67 − strike price), using the most recent insider trade price on Form 4 (Sep 16, 2026), not a market close.

Holdings and share of stake for MapLight Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$29.2M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $29.2M across 986,277 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $20.0M · 69%

31%

The lighter segment is sales with no plan disclosed in the filing ($9.1M), including tax-related sales outside a plan.

Taxes

$11.7M of sales (40.1%) cite tax obligations in their footnotes, $2.6M of them also under a plan. Separately, 417,355 shares ($7.5M) were withheld by the company for taxes, which isn't a market sale. Example: James Lillie, Jul 17, 2026

Purchases · 3 buyers (5 trades)

3 officers and directors bought shares in this period, in 5 trades(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 5 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Christopher Kroeger Chief Executive Officer, Director	403K	$12.5M	52%	43%	Apr 15, 2026 to Jul 17, 2026
Jonathan Gillis CAO and Interim CFO	110K	$3.6M	97%	12%	Apr 15, 2026 to Jul 17, 2026
Erin Foff Chief Medical Officer	105K	$3.4M	97%	12%	Apr 15, 2026 to Jul 17, 2026
Anatol Kreitzer Chief Discovery Officer	85K	$2.8M	97%	10%	Apr 15, 2026 to Jul 17, 2026
James Lillie Chief Scientific Officer	97K	$2.6M	69%	9%	Apr 15, 2026 to Aug 3, 2026
Kristopher Hanson General Counsel	63K	$1.7M	60%	6%	Apr 15, 2026 to Sep 16, 2026
Robert Malenka Director	83K	$1.6M	14%	5%	Jan 28, 2026 to Apr 15, 2026
Vishwas Setia Chief Financial Officer	39K	$1.1M	93%	4%	Apr 15, 2026 to May 6, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$636K	$0	$636K	$0
Feb 2026	$732K	$0	$732K	$0
Mar 2026	$0	$0	$0	$0
Apr 2026	$4.7M	$3.7M	$1.0M	$0
May 2026	$11.5M	$11.5M	$0	$0
Jun 2026	$0	$0	$0	$0
Jul 2026	$11.2M	$4.5M	$6.7M	$0
Aug 2026	$277K	$277K	$0	$0
Sep 2026	$193K	$193K	$0	$0
Oct 2026	$0	$0	$0	$0

Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for MapLight Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology94 filings on record, 94 filed in the 12-month period, and how we read them

All 94 Forms 3, 4 and 5 on record for MapLight Therapeutics, Inc. (SEC CIK 1770069), filed from Oct 27, 2025 to Sep 18, 2026; 94 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (1)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
James Trenkle		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

MapLight Therapeutics, Inc. insiders sold $29.2M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the MapLight Therapeutics, Inc. CEO selling stock?

Why are MapLight Therapeutics, Inc. insiders selling?

Are any MapLight Therapeutics, Inc. insiders buying?

The evidence

Taxes

Purchases · 3 buyers (5 trades)

Sales by month